United Kingdom Gout Treatment Market Insight
The United Kingdom Gout Treatment Market is growing at an 11.8% CAGR, driven by NHS access, rising prevalence, and aging populations. Increasing use of urate-lowering therapies and innovations by Takeda Pharmaceutical Company improve treatment effectiveness, safety, and long-term outcomes
United Kingdom Gout Treatment Market Insights Forecasts to 2035
- The United Kingdom Gout Treatment Market Size Was Estimated at USD 4.01 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.8% from 2025 to 2035
- The United Kingdom Gout Treatment Market Size is Expected to Reach USD 12.23 Billion by 2035
Notable Insights for United Kingdom Gout Treatment Market
- By product type, urate-lowering drugs dominated, accounting for approximately 40–45% share in 2024, driven by widespread use of first-line therapies such as allopurinol for long-term uric acid control.
- By disease type, chronic gout dominated, holding approximately 60–65% share, due to the need for continuous treatment to maintain serum urate levels below recommended thresholds.
- Approximately 2–3% of the UK adult population is affected by gout, with prevalence rising to over 7% among men aged above 65 years.
The UK accounts for approximately 12–15% of Europe’s gout treatment market, with over 80% of patients receiving treatment through NHS services, supporting high treatment accessibility
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Gout Treatment Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Gout Treatment Market
- Takeda Pharmaceutical Company
- Horizon Therapeutics
- AstraZeneca
- Novartis AG
- Merck & Co.
- GlaxoSmithKline
- Regeneron Pharmaceuticals
- Teijin Pharma
- Pfizer Inc.
- Selecta Biosciences
- Others
Recent Developments:
- In February 2026, Sobi announced acquisition of Arthrosi Therapeutics in December 2025 to advance pozdeutinurad (AR882), a Phase 3 URAT1 inhibitor for refractory gout, with potential future impact on UK treatment landscape.
- In March 2023: Sobi and Selecta Biosciences announced positive Phase 3 results for SEL-212, a combination therapy for chronic refractory gout, showing strong efficacy and supporting future regulatory filings.
Market Segmentation:
United Kingdom Gout Treatment Market, By Product Type
- Urate-Lowering Drugs
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Colchicine
- Corticosteroids
- Biologics
United Kingdom Gout Treatment Market, By Disease Type
- Acute Gout
- Chronic Gout
United Kingdom Gout Treatment Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Gout Treatment Market is expected to grow steadily due to increasing prevalence of gout and rising demand for long-term disease management solutions. Experts highlight that urate-lowering therapies, biologics, and improved anti-inflammatory treatments will dominate the market. With rising awareness and strong public healthcare support, demand for safe, effective, and long-term gout management solutions is expected to increase, ensuring sustained market growth.